US Intravenous Immunoglobulin Market

ID: MRFR/Pharma/11450-HCR
100 Pages
Satyendra Maurya
Last Updated: April 06, 2026
US Intravenous Immunoglobulin Market Research Report: Size, Share, Trend Analysis By Applications (Immunodeficiency Disorders, Neurological Disorders, Autoimmune Disorders, Infectious Diseases), By End Use (Hospitals, Clinics, Homecare, Pharmaceutical Companies), By Product Type (Intravenous Immunoglobulin, Subcutaneous Immunoglobulin, Combination Therapies) and By Source (Human Plasma, Recombinant Techniques) - Growth Outlook & Industry Forecast 2025 To 2035
US Intravenous Immunoglobulin Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)3.75%
2024 Market Size$ 2,700 Million
2025 Market Size$ 2,801.25 Million
2035 Market Size$ 4,050 Million
Key Players
Grifols
CSL Behring
Octapharma
Kedrion
Takeda
Baxter
Trends
  • Rising Demand for Immunotherapy
  • Technological Advancements in Production
  • Focus on Patient-Centric Approaches
Opportunities
  • Growing Geriatric Population
  • Expansion of Healthcare Infrastructure
  • Rising Awareness of Immunoglobulin Therapy
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Security, Access Control and Robotics, BY Application (USD Million)
      1. 4.1.1 Immunodeficiency Disorders
      2. 4.1.2 Neurological Disorders
      3. 4.1.3 Autoimmune Disorders
      4. 4.1.4 Infectious Diseases
    2. 4.2 Security, Access Control and Robotics, BY End-Use (USD Million)
      1. 4.2.1 Hospitals
      2. 4.2.2 Clinics
      3. 4.2.3 Homecare
      4. 4.2.4 Pharmaceutical Companies
    3. 4.3 Security, Access Control and Robotics, BY Product Type (USD Million)
      1. 4.3.1 Intravenous Immunoglobulin
      2. 4.3.2 Subcutaneous Immunoglobulin
      3. 4.3.3 Combination Therapies
    4. 4.4 Security, Access Control and Robotics, BY Source (USD Million)
      1. 4.4.1 Human Plasma
      2. 4.4.2 Recombinant Techniques
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Security, Access Control and Robotics
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Security, Access Control and Robotics
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Grifols (ES)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 CSL Behring (AU)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Octapharma (CH)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Kedrion (IT)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Takeda (JP)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Baxter (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 LFB (FR)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Biotest (DE)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY APPLICATION
    3. 6.3 US MARKET ANALYSIS BY END-USE
    4. 6.4 US MARKET ANALYSIS BY PRODUCT TYPE
    5. 6.5 US MARKET ANALYSIS BY SOURCE
    6. 6.6 KEY BUYING CRITERIA OF SECURITY, ACCESS CONTROL AND ROBOTICS
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF SECURITY, ACCESS CONTROL AND ROBOTICS
    9. 6.9 DRIVERS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
    11. 6.11 SUPPLY / VALUE CHAIN: SECURITY, ACCESS CONTROL AND ROBOTICS
    12. 6.12 SECURITY, ACCESS CONTROL AND ROBOTICS, BY APPLICATION, 2024 (% SHARE)
    13. 6.13 SECURITY, ACCESS CONTROL AND ROBOTICS, BY APPLICATION, 2024 TO 2035 (USD Million)
    14. 6.14 SECURITY, ACCESS CONTROL AND ROBOTICS, BY END-USE, 2024 (% SHARE)
    15. 6.15 SECURITY, ACCESS CONTROL AND ROBOTICS, BY END-USE, 2024 TO 2035 (USD Million)
    16. 6.16 SECURITY, ACCESS CONTROL AND ROBOTICS, BY PRODUCT TYPE, 2024 (% SHARE)
    17. 6.17 SECURITY, ACCESS CONTROL AND ROBOTICS, BY PRODUCT TYPE, 2024 TO 2035 (USD Million)
    18. 6.18 SECURITY, ACCESS CONTROL AND ROBOTICS, BY SOURCE, 2024 (% SHARE)
    19. 6.19 SECURITY, ACCESS CONTROL AND ROBOTICS, BY SOURCE, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY APPLICATION, 2025-2035 (USD Million)
      2. 7.2.2 BY END-USE, 2025-2035 (USD Million)
      3. 7.2.3 BY PRODUCT TYPE, 2025-2035 (USD Million)
      4. 7.2.4 BY SOURCE, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Intravenous Immunoglobulin Market Segmentation

US Intravenous Immunoglobulin Market By Application (USD Million, 2025-2035)

  • Immunodeficiency Disorders
  • Neurological Disorders
  • Autoimmune Disorders
  • Infectious Diseases

US Intravenous Immunoglobulin Market By End-Use (USD Million, 2025-2035)

  • Hospitals
  • Clinics
  • Homecare
  • US Intravenous Immunoglobulin Market Companies

US Intravenous Immunoglobulin Market By Product Type (USD Million, 2025-2035)

  • Intravenous Immunoglobulin
  • Subcutaneous Immunoglobulin
  • Combination Therapies

US Intravenous Immunoglobulin Market By Source (USD Million, 2025-2035)

  • Human Plasma
  • Recombinant Techniques

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.